To assess more stringent requirements that may functionally demonstrate the exhaustive phenotype shown in the CAR T cell products, we next examined the ex vivo expansion potential and IL-2 production of patient-derived CAR T cells (n = 22) upon exposure to tumor cells. The gene discussed is IL2; the disease is neoplasm.